Latest news with #surgical
Associated Press
2 days ago
- Business
- Associated Press
Movora Becomes Exclusive Distributor of Aesculap Surgical Power Systems in North America
St. Augustine, Florida--(Newsfile Corp. - July 21, 2025) - As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada. This partnership further strengthens Movora's commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap's innovative power systems, reinforcing its role as a leader in the veterinary surgical space. 'Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market,' said Guy Spörri, CEO of Movora. 'This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies.' Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: 'We are very much looking forward to our continued cooperation and hope for further successful business together.' The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada. Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit for more information and to get started. For more information, visit Media Contacts: Korrie Wilhelm, VP Global MarCom, Brand Strategy & Ecommerce Movora Achim Ott, Export Sales Manager BBraun VetCare/Aesculap [email protected] To view the source version of this press release, please visit
Yahoo
2 days ago
- Business
- Yahoo
Movora Becomes Exclusive Distributor of Aesculap Surgical Power Systems in North America
St. Augustine, Florida--(Newsfile Corp. - July 21, 2025) - As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada. This partnership further strengthens Movora's commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap's innovative power systems, reinforcing its role as a leader in the veterinary surgical space. "Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market," said Guy Spörri, CEO of Movora. "This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies." Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: "We are very much looking forward to our continued cooperation and hope for further successful business together." The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada. Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit for more information and to get started. For more information, visit Media Contacts:Korrie Wilhelm, VP Global MarCom, Brand Strategy & Achim Ott, Export Sales ManagerBBraun VetCare/ To view the source version of this press release, please visit Sign in to access your portfolio
CNA
14-07-2025
- Business
- CNA
Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio
Zimmer Biomet it will acquire robotics firm Monogram Technologies for about $177 million, adding Monogram's semi- and fully autonomous surgical products to its expanding robotics portfolio, the companies said on Monday Shares of Monogram more than doubled to $6.70 in premarket trading. WHY IT'S IMPORTANT Medical device makers, including larger peers Medtronic and Johnson & Johnson are seeking to strengthen their robotic surgery offerings. The global market for robotic surgery devices is expected to be worth nearly $16 billion by the end of this decade, according to data analytics firm GlobalData. The deal will allow Warsaw, Indiana-based Zimmer to broaden its robotics platform and gain access to Monogram's semi-autonomous knee replacement technology, which was approved by the U.S. Food and Drug Administration in March 2025. Zimmer expects to integrate Monogram's technology and launch fully autonomous surgical robots and additional applications beyond prosthetic knee replacement by 2027. BY THE NUMBERS Monogram stockholders will receive $4.04 per share in cash upfront, which represents a premium of 22.8 per cent to its last close. The terms also include up to $12.37 per share in contingent value rights, dependent on certain milestones being met by 2030. Zimmer Biomet plans to fund the deal with a combination of cash and available debt financing. WHAT'S NEXT The deal is expected to close later this year. Zimmer expects the deal to be neutral to adjusted earnings per share until 2027, and accretive to earnings from 2028 onward.
Reuters
14-07-2025
- Business
- Reuters
Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio
July 14 (Reuters) - Zimmer Biomet (ZBH.N), opens new tab it will acquire robotics firm Monogram Technologies (MGRM.O), opens new tab for about $177 million, adding Monogram's semi- and fully autonomous surgical products to its expanding robotics portfolio, the companies said on Monday Shares of Monogram more than doubled to $6.70 in premarket trading. WHY IT'S IMPORTANT Medical device makers, including larger peers Medtronic (MDT.N), opens new tab and Johnson & Johnson (JNJ.N), opens new tab are seeking to strengthen their robotic surgery offerings. The global market for robotic surgery devices is expected to be worth nearly $16 billion by the end of this decade, according to data analytics firm GlobalData. The deal will allow Warsaw, Indiana-based Zimmer to broaden its robotics platform and gain access to Monogram's semi-autonomous knee replacement technology, which was approved by the U.S. Food and Drug Administration in March 2025. Zimmer expects to integrate Monogram's technology and launch fully autonomous surgical robots and additional applications beyond prosthetic knee replacement by 2027. Monogram stockholders will receive $4.04 per share in cash upfront, which represents a premium of 22.8% to its last close. The terms also include up to $12.37 per share in contingent value rights, dependent on certain milestones being met by 2030. Zimmer Biomet plans to fund the deal with a combination of cash and available debt financing. The deal is expected to close later this year. Zimmer expects the deal to be neutral to adjusted earnings per share until 2027, and accretive to earnings from 2028 onward.
Yahoo
14-07-2025
- Business
- Yahoo
Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio
(Reuters) -Zimmer Biomet it will acquire robotics firm Monogram Technologies for about $177 million, adding Monogram's semi- and fully autonomous surgical products to its expanding robotics portfolio, the companies said on Monday Shares of Monogram more than doubled to $6.70 in premarket trading. WHY IT'S IMPORTANT Medical device makers, including larger peers Medtronic and Johnson & Johnson are seeking to strengthen their robotic surgery offerings. The global market for robotic surgery devices is expected to be worth nearly $16 billion by the end of this decade, according to data analytics firm GlobalData. The deal will allow Warsaw, Indiana-based Zimmer to broaden its robotics platform and gain access to Monogram's semi-autonomous knee replacement technology, which was approved by the U.S. Food and Drug Administration in March 2025. Zimmer expects to integrate Monogram's technology and launch fully autonomous surgical robots and additional applications beyond prosthetic knee replacement by 2027. BY THE NUMBERS Monogram stockholders will receive $4.04 per share in cash upfront, which represents a premium of 22.8% to its last close. The terms also include up to $12.37 per share in contingent value rights, dependent on certain milestones being met by 2030. Zimmer Biomet plans to fund the deal with a combination of cash and available debt financing. WHAT'S NEXT The deal is expected to close later this year. Zimmer expects the deal to be neutral to adjusted earnings per share until 2027, and accretive to earnings from 2028 onward.
